To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
113 Current news about the topic abbott
rss
Abbott completes separation of research-based pharmaceuticals business
08-01-2013
Abbott announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV." "We wish our colleagues at AbbVie ...
Abbott's HUMIRA (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn's Disease
29-11-2012
Abbott announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA ...
Abbott to Collaborate with Astellas in CMV Vaccine Trial
10-09-2012
Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant ...
Abbott's HUMIRA Approved in Europe for Expanded Treatment of Crohn's Disease (CD)
31-08-2012
Abbott announced that the European Commission (EC) has approved HUMIRA® (adalimumab) for the treatment of moderately active Crohn's disease (CD) in adult patients who have had an inadequate response to conventional therapy. HUMIRA has been approved for severely active CD in adults in the ...
Abbott Again Named One of the Best Workplaces in Europe
22-06-2012
The Great Place to Work® Institute named Abbott one of the Best Multinational Workplaces in Europe at its European Awards event in Berlin. The company was specifically honored for workplace leadership in Belgium, Denmark, Ireland, Norway and Portugal. This is the third consecutive year that ...
Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
07-05-2012
Abbott and Action Pharma A/S announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in ...
Abbott Announces Collaboration with Syngene to Open Nutrition R&D Center
03-05-2012
Abbott announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene. The Abbott Nutrition R&D Center in India will focus on the development of science-based, affordable nutrition products for the country and enable the expansion ...
Abbott's HUMIRA Approved in Europe for Treatment of Ulcerative Colitis
12-04-2012
Abbott announced that the European Commission has approved HUMIRA®(adalimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy. With this approval, HUMIRA becomes the first and only ...
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Company Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
22-03-2012
Abbott announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012.The naming of the new company is the latest milestone in the process that began in October 2011, when Abbott announced it ...
Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA (adalimumab) for Moderate to Severe Hidradenitis Suppurativa
Key Clinical Trials will Assess Drug's Efficacy and Safety
19-03-2012
Abbott announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS).Hidradenitis suppurativa is a difficult-to-treat, chronic, ...
Netmeeting
